Table 2:
Estimated hazard ratios from a multivariate multi-state model, aHR (95% CI)
| Sex | Age at ART initiation (years) | Year of ART start | Immune status | VL | ART regimen | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Girls | 1–2 | 2–5 | 2010–2012 | 2013–2020 | SIS at ART start | VL≥1000 | VL missing | PI | ||
| reference | Boys | 0–1 | 2007–2009 | not SIS at ART start | VL<1000 copies/ml | NNRTI | ||||
| Early Gap to | ||||||||||
| SIS | 1.1 (0.62–1.95) | 0.92 (0.44–1.91) | 1.15 (0.52–2.55) | 1.05 (0.47–2.36) | 1.91 (0.92–4) | 2.14 (0.97–4.72) | 1 (1–1) | 1 (1–1) | 2.65 (0.91–7.72) | |
| Stable | 0.68 (0.42–1.11) | 1.07 (0.58–1.97) | 1.31 (0.66–2.61) | 0.73 (0.42–1.27) | 0.56 (0.31–1.04) | 0.42 (0.26–0.67) | 1 (1–1) | 1 (1–1) | 1.29 (0.62–2.68) | |
| Death | 0.04 (0–1821.61) | 0.09 (0–662.34) | 0.1 (0–18786.88) | 0.05 (0–502) | 0.05 (0–931.72) | 4.97 (0–887192.56) | 1 (1–1) | 1 (1–1) | 4.6 (0–2268559504.22) | |
| SIS on ART to | ||||||||||
| Stable | 1.16 (1–1.35) | 0.8 (0.66–0.96) | 0.84 (0.68–1.05) | 0.62 (0.52–0.75) | 0.75 (0.62–0.9) | 0.89 (0.71–1.12) | 0.78 (0.66–0.91) | 0.92 (0.67–1.27) | 1.08 (0.81–1.44) | |
| Late Gap | 1.25 (0.9–1.73) | 1.19 (0.8–1.77) | 1.09 (0.67–1.76) | 1.18 (0.8–1.73) | 1.25 (0.84–1.86) | 0.72 (0.45–1.14) | 1.13 (0.81–1.59) | 1.96 (1.04–3.69) | 1.27 (0.67–2.39) | |
| Death | 0.93 (0.34–2.59) | 0.76 (0.24–2.39) | 0 (0–123636880599010000) | 0.48 (0.13–1.8) | 0.59 (0.18–1.95) | 1.23 (0.16–9.29) | 5.88 (1.65–20.97) | 0.15 (0–1370.66) | 28.39 (0–51338765061.68) | |
| Stable on ART to | ||||||||||
| SIS | 0.81 (0.61–1.06) | 0.74 (0.52–1.05) | 0.55 (0.36–0.86) | 0.75 (0.54–1.02) | 0.55 (0.38–0.81) | 1.71 (1.21–2.41) | 2.08 (1.53–2.83) | 3.12 (1.81–5.36) | 1.2 (0.7–2.05) | |
| Late Gap | 1.05 (0.95–1.16) | 1.02 (0.89–1.16) | 1 (0.86–1.16) | 1.24 (1.1–1.39) | 1.03 (0.9–1.18) | 1.07 (0.96–1.2) | 0.96 (0.83–1.1) | 1.69 (1.33–2.15) | 1.18 (0.99–1.4) | |
| Death | 0.97 (0.34–2.78) | 1.39 (0.46–4.17) | 0 (0–266432932453167) | 0.97 (0.27–3.49) | 1.13 (0.31–4.1) | 0.94 (0.29–3.03) | 5.09 (1.63–15.93) | 7.33 (1.44–37.16) | 36.76 (0–1941653017356.1) | |
| Late Gap to | ||||||||||
| SIS | 0.45 (0.19–1.09) | 0.73 (0.26–2.01) | 0.87 (0.31–2.42) | 0.87 (0.37–2.04) | 1.18 (0.43–3.26) | 1.65 (0.58–4.68) | 1 (1–1) | 1 (1–1) | 1.13 (0.32–3.94) | |
| Stable | 1.54 (1.08–2.2) | 0.72 (0.47–1.09) | 0.3 (0.15–0.62) | 0.59 (0.39–0.89) | 0.72 (0.46–1.15) | 0.9 (0.62–1.31) | 1 (1–1) | 1 (1–1) | 1.41 (0.55–3.58) | |
| Death | 0.01 (0–42220.15) | 2.66 (0.16–45.02) | 0.07 (0–19356.71) | 24.41 (0–120974.53) | 36.97 (0.01–183950.65) | 34.34 (0–9858840.11) | 1 (1–1) | 1 (1–1) | 3.99 (0–5523301.08) | |
Bold indicates the confidence interval does not include the null
ART: Antiretroviral treatment
SIS: Severe immune suppression
SIS on ART: SIS after ART start
Stable on ART: Not SIS after ART start
Gap in care: no recorded visit for ≥9 months
Early Gap: gap in care commencing ≤9 months from ART start
Late Gap: gap in care commencing >9 months from ART start
NNRTI: non-nucleoside reverse transcriptase inhibitor
PI: protease inhibitor
VL: viral load